Health and Me

Ishita Roy

Flourishing Doesn't Mean Happiness, Youth Is Struggling, Finds Study

Flourishing Does Not Mean Happiness, Finds Study

A new study titled <em>The Global Flourishing Study,</em> conducted by researchers from Baylor and Harvard universities have thrown light on the meaning of "flourishing" and how it does not mean being happy. The study has looked at how some countries are doing significantly better in terms of the broader sense of well-being than other countries. The study is based on responses from over 207,000 participants across 22 countries and Hong Kong. The study also assessed six core aspects of flourishing, which includes happiness, health, meaning, character, relationships, and financial stability. 

<h4>What Does Being "Flourished" Really Mean?</h4>

While there are traditional happiness indexes that measures an individual's or a group's subjective well-being or happiness, the study about being "flourished" includes not just how happy people feel, but also their health. The study looks at whether people are leading a healthy life, whether they are mentally well and feel like they do have a purpose in life. The study also takes in account for strong relationships, acting with character and feeling financially secure. 

The participants of this study were asked to respond to 12 key questions. They were aimed at measuring these components. The questions varied from "How satisfied are you with life?" to "Do you worry about meeting monthly expenses?"

Dr. Byron Johnson of Baylor University, who led the study, said the scale of the research is what makes it especially unique. “We are following 207,000 participants around the world in over 40 languages. This gives a voice to approximately 64% of the world’s population,” he explained.

<h4>Indonesia Leads, But Traditionally 'Happy' Nations Lag</h4>

The results too have been unexpected, unlike what we seen in the happiness indexes. Countries which were often seen as happy in global rankings did not perform as well when it came to flourishing. Indonesia, however, topped the list, followed by Mexico and the Philippines. However, nations like Sweden and the United States, which are usually high ranking in the World Happiness Report, were found to be average in terms of flourishing. 

Interestingly, some of the most flourishing countries, such as Nigeria and Indonesia, did not make it to the top 20 in the World Happiness Report, indicating a crucial distinction between simple happiness and a deeper sense of well-being.

One of the most concerning findings of the study was that flourishing tends to increase with age. According to Dr. Tyler VanderWeele of the Harvard T.H. Chan School of Public Health, young people across most countries reported the lowest levels of flourishing, often citing a lack of purpose.

"In most countries, the youngest individuals are the ones struggling the most,” VanderWeele noted. However, there were exceptions—Tanzania and Poland showed relatively better flourishing scores among their younger populations.

The researchers suggest that in more developed countries, increased competition, job stress, and social comparison may be contributing to this generational dip. “Young people are telling us something is wrong,” added Felix Cheung, a co-author of a separate study in the World Happiness Report.

While wealthier countries usually scored higher in the financial security section, they lacked in the sections where they were asked questions on meaning and relationships. 

This gap has raised questions about modern development. “How can we carry out economic growth without compromising meaning and relationships?” VanderWeele asked.

In contrast, countries with fewer economic resources but stronger community bonds and clearer cultural or spiritual values often performed better on overall flourishing metrics.

According to researchers, people can take active steps to improve their own flourishing. VanderWeele shared how one participant, after reflecting on the study’s 12 questions, decided to volunteer to find greater purpose. “Flourishing can be guided by reflection,” he said.

Still, systemic issues like conflict, inequality, and poor governance remain significant barriers. As Cheung summed it up: “When one person is unhappy, that’s an individual issue. But when a population isn’t happy, that’s a structural problem—and it requires structural solutions.”

Health Conditions A-Z

health

flourishing index

health news

happiness index

mental health

life satisfaction

health news USA

What Is The Viral Cortisol Cocktail? Does It Really Work?

New Texas Law Could Change Labeling Of Food Additives Across US

Measles Outbreak: North Carolina Confirms Its First Case Of 2025

Health News

High-Protein No Cook Dishes You Should Try

Yoga Poses That Aid In Digestion

Low Calorie Dinner Options For Weight Loss

Cardiac Arrest Vs. Heart Attack: Difference Explained Under 60 Seconds

High Protein Low-Carb Snacks To Have On The Go

Knee Exercises Desk Workers Should Do For Joint Health

Why Do I Feel Sleepy During The Day?

High Protein Early Morning Meals To Keep You Full Till Lunch

International Yoga Day 2025: Benefits of Doing Tadasana Every Morning

High-Carb Foods That Are Really Healthy

Dementia Vs Alzheimer’s: Difference Explained Under 60 Seconds

Healthy Staple Foods To Make Eating Healthy Easier

Are You Dealing With Abandonment Issues? Signs And Risk Factors

Mid-Work Healthy Snacks You Can Eat Throughout The Day

Common Mistakes You May Be Making In The Gym

Strengthen Your Legs Muscles With These Exercises

Beat Anxiety With Books: How Reading Helps With Stress

Ghee For Health: Ayurvedic Health Benefits Of Clarified Butter

Common Mistakes You Are Making While Walking

Exercises You Should Do At Home When You Skip Gym

Common Mistakes You May Be Making While Working Out

Ways You Are Runing Your Weight Loss Journey

Beyond Fruits – How To Retain Hydration And Stay Safe In Summers

Can This Extremely Hot Weather Trigger Our Mental Health?

You Are Hurting Your Gut Health With These Habits

Avoid The Heat With These Indoor Exercises

Stay Sharp! Activities That Keep Cognitive Diseases At Bay

Protect Your Cardiovascular Health With These Heart Healthy Foods

Ways To Ease Nighttime Anxiety

Smoothie Ideas That Can Help With Weight Loss

Low Fat Foods That Are Actually Unhealthy

All Suryanamaskar Poses And How To Do Them

Do Changing Seasons Affect Your Weight?

Can Heatwave Affect Your Diet?

Heatwave To Monsoon: Health Concerns With Seasonal Changes

Standing Exercises That Help You Burn Calories

Reasons To Do Dancing As A Workout

Why Summer Fruits Are A Great Addition To Your Diet?

What Should You Avoid For Your Bladder?

Lower-Body Exercises For Strong Foundation

A new study titled The Global Flourishing Study, conducted by researchers from Baylor and Harvard universities have thrown light on the meaning of "flourishing" and how it does not mean being happy. The study has looked at how some countries are doing significantly better in terms of the broader sense of well-being than other countries. The study is based on responses from over 207,000 participants across 22 countries and Hong Kong. The study also assessed six core aspects of flourishing, which includes happiness, health, meaning, character, relationships, and financial stability. What Does Being "Flourished" Really Mean?While there are traditional happiness indexes that measures an individual's or a group's subjective well-being or happiness, the study about being "flourished" includes not just how happy people feel, but also their health. The study looks at whether people are leading a healthy life, whether they are mentally well and feel like they do have a purpose in life. The study also takes in account for strong relationships, acting with character and feeling financially secure. The participants of this study were asked to respond to 12 key questions. They were aimed at measuring these components. The questions varied from "How satisfied are you with life?" to "Do you worry about meeting monthly expenses?"Dr. Byron Johnson of Baylor University, who led the study, said the scale of the research is what makes it especially unique. “We are following 207,000 participants around the world in over 40 languages. This gives a voice to approximately 64% of the world’s population,” he explained.Indonesia Leads, But Traditionally 'Happy' Nations LagThe results too have been unexpected, unlike what we seen in the happiness indexes. Countries which were often seen as happy in global rankings did not perform as well when it came to flourishing. Indonesia, however, topped the list, followed by Mexico and the Philippines. However, nations like Sweden and the United States, which are usually high ranking in the World Happiness Report, were found to be average in terms of flourishing. Interestingly, some of the most flourishing countries, such as Nigeria and Indonesia, did not make it to the top 20 in the World Happiness Report, indicating a crucial distinction between simple happiness and a deeper sense of well-being.Youth Is StrugglingOne of the most concerning findings of the study was that flourishing tends to increase with age. According to Dr. Tyler VanderWeele of the Harvard T.H. Chan School of Public Health, young people across most countries reported the lowest levels of flourishing, often citing a lack of purpose."In most countries, the youngest individuals are the ones struggling the most,” VanderWeele noted. However, there were exceptions—Tanzania and Poland showed relatively better flourishing scores among their younger populations.The researchers suggest that in more developed countries, increased competition, job stress, and social comparison may be contributing to this generational dip. “Young people are telling us something is wrong,” added Felix Cheung, a co-author of a separate study in the World Happiness Report.Rich, Not FlourishingWhile wealthier countries usually scored higher in the financial security section, they lacked in the sections where they were asked questions on meaning and relationships. This gap has raised questions about modern development. “How can we carry out economic growth without compromising meaning and relationships?” VanderWeele asked.In contrast, countries with fewer economic resources but stronger community bonds and clearer cultural or spiritual values often performed better on overall flourishing metrics.According to researchers, people can take active steps to improve their own flourishing. VanderWeele shared how one participant, after reflecting on the study’s 12 questions, decided to volunteer to find greater purpose. “Flourishing can be guided by reflection,” he said.Still, systemic issues like conflict, inequality, and poor governance remain significant barriers. As Cheung summed it up: “When one person is unhappy, that’s an individual issue. But when a population isn’t happy, that’s a structural problem—and it requires structural solutions.”

flourishing doesn't mean happiness, youth is struggling, finds study

10 Worst US Cities To Live In During Seasonal Allergies

10 worst us cities to live in during seasonal allergies

These Are The Unusual Symptoms Of The Newly Identified COVID-19 Variant NB.1.8.1

these are the unusual symptoms of the newly identified covid-19 variant nb.1.8.1

Former Anti-Vaccine Leader to Weigh In On CDC Vaccine Strategy

former anti-vaccine leader to weigh in on cdc vaccine strategy

Health & Wellness

Nearly 30 People in England Get Rare Illness After Botox; How Safe Are Cosmetic Procedures, Really?

nearly 30 people in england get rare illness after botox; how safe are cosmetic procedures, really?

Amid the ongoing <span>measles</span> outbreak in the United States, the state of North Carolina has confirmed its first case in 2025. The North Carolina Department of Health and Human Services (NCDHHS) confirmed a case of measles in a child who was visiting Forsyth County and Guilford County. 

The child became ill while traveling to North Carolina from a region where measles had already been reported. The news is confirmed as per the NCDHHS release. 

The authorities are now also asking people who have visited the below mentioned location to review their immunization records or contact a healthcare provider to ensure that you are updated with the measles-mumps-rubella vaccine. 

<ul><li>PTI Airport in Greensboro</li><li>Sleep Inn, 1406 Heartland Dr., Kernersville</li><li>McDonalds, 14000 Heartland Dr., Kernersville</li><li>Greensboro Science Center, 4301 Lawndale Dr., Greensboro</li><li>Ice cream shop at Piedmont Triad Farmers Market, Greensboro</li><li>Greensboro Aquatic Center Foyer, 1921 W. Gate City Blvd., Greensboro</li><li>Greensboro Partee Shack, 3712 S. Holden Rd., Greensboro</li><li>Lowes Foods, 240 Market View Dr., Kernersville</li></ul>

The NCDHHS has also recommended that anyone unvaccinated and older than one year must get the measles vaccination. 

However, when it comes to lab tests, the NCDHHS recommends that it is not necessary for people who were exposed, unless they develop symptoms of measles, including fever and rash. These symptoms can start from 7 to 21 days of getting infected. “Getting vaccinated against measles continues to be the most important step we can take to protect ourselves and our loved ones,” NCDHHS Secretary Dev Sangvai said. “It is important to check with your health care provider to ensure you are current with all your vaccines.” 

As per the Centers for Disease Control and Prevention (CDC), measles is a highly contagious disease that comes with rashes and are especially prone to kids under the age of 5. 

If one person gets it then 9 out of 10 people around the infected person may become infected.

Measles, also known as rubeola, is one of the most contagious infectious diseases, with at least a 90% secondary infection rate in susceptible domestic contacts. It can affect people of all ages, despite being considered primarily a childhood illness. 

Measles is marked by prodromal fever, cough, coryza, conjunctivitis, and pathognomonic enanthem (ie, Koplik spots), followed by an erythematous maculopapular rash on the third to seventh day. 

The World Health Organization (WHO), calls measles as one of the world's most contagious disease, which is spread by contact with infected nasal or throat secretions through coughing or sneezing, or breathing the air that was breathed by someone with measles. The virus remains active and contagious in the air or on infected surfaces for up to two hours. 

WHO notes that any non-immune person (not vaccinated or vaccinated but did not develop immunity) can become infected. Unvaccinated young children and pregnant persons are at highest risk of severe measles complications.

measles

north carolina first measles case

health news us

us health news

Amid the ongoing measles outbreak in the United States, the state of North Carolina has confirmed its first case in 2025. The North Carolina Department of Health and Human Services (NCDHHS) confirmed a case of measles in a child who was visiting Forsyth County and Guilford County. How Did The Child Fall Sick?The child became ill while traveling to North Carolina from a region where measles had already been reported. The news is confirmed as per the NCDHHS release. The authorities are now also asking people who have visited the below mentioned location to review their immunization records or contact a healthcare provider to ensure that you are updated with the measles-mumps-rubella vaccine. The Locations Are:PTI Airport in GreensboroSleep Inn, 1406 Heartland Dr., KernersvilleMcDonalds, 14000 Heartland Dr., KernersvilleGreensboro Science Center, 4301 Lawndale Dr., GreensboroIce cream shop at Piedmont Triad Farmers Market, GreensboroGreensboro Aquatic Center Foyer, 1921 W. Gate City Blvd., GreensboroGreensboro Partee Shack, 3712 S. Holden Rd., GreensboroLowes Foods, 240 Market View Dr., KernersvilleWhat Are The safety Guidelines?The NCDHHS has also recommended that anyone unvaccinated and older than one year must get the measles vaccination. However, when it comes to lab tests, the NCDHHS recommends that it is not necessary for people who were exposed, unless they develop symptoms of measles, including fever and rash. These symptoms can start from 7 to 21 days of getting infected. “Getting vaccinated against measles continues to be the most important step we can take to protect ourselves and our loved ones,” NCDHHS Secretary Dev Sangvai said. “It is important to check with your health care provider to ensure you are current with all your vaccines.” What Is Measles?As per the Centers for Disease Control and Prevention (CDC), measles is a highly contagious disease that comes with rashes and are especially prone to kids under the age of 5. If one person gets it then 9 out of 10 people around the infected person may become infected.Measles, also known as rubeola, is one of the most contagious infectious diseases, with at least a 90% secondary infection rate in susceptible domestic contacts. It can affect people of all ages, despite being considered primarily a childhood illness. Measles is marked by prodromal fever, cough, coryza, conjunctivitis, and pathognomonic enanthem (ie, Koplik spots), followed by an erythematous maculopapular rash on the third to seventh day. Who Is At Risk?The World Health Organization (WHO), calls measles as one of the world's most contagious disease, which is spread by contact with infected nasal or throat secretions through coughing or sneezing, or breathing the air that was breathed by someone with measles. The virus remains active and contagious in the air or on infected surfaces for up to two hours. WHO notes that any non-immune person (not vaccinated or vaccinated but did not develop immunity) can become infected. Unvaccinated young children and pregnant persons are at highest risk of severe measles complications.

measles outbreak: north carolina confirms its first case of 2025

Tanya Dutt

Not Wegovy or Mounjaro Or Ozempic: This New Monthly Weight Loss Jab Helped People Drop 20% Body Fat

Wegovy vs. Mounjaro: Which Weight-Loss Jab Works Best?

wegovy vs. mounjaro: which weight-loss jab works best?

Novo Nordisk Launches Bestseller Weight Loss Drug Wegovy In India

novo nordisk launches bestseller weight loss drug wegovy in india

Mounjaro For Weight Loss: How It Works, Duration, Side Effects, Cost And More

mounjaro for weight loss: how it works, duration, side effects, cost and more

Nutrition

Feast, Famine And Fat Loss: New Diet Trend 'Better Than Intermittent Fasting' Could Help You Lose Weight Faster

feast, famine and fat loss: new diet trend 'better than intermittent fasting' could help you lose weight faster

A new clinical trial has uncovered the breakthrough promise of a <span>new weight loss medication</span>, MariTide, that can be taken only once monthly. Amgen developed the investigational drug, and it has demonstrated remarkable weight loss outcomes up to 20% in individuals with obesity. The Phase 2 trial results, which were released in The New England Journal of Medicine and presented at the American Diabetes Association's annual meeting 2025, may be a turning point in the treatment of obesity and Type 2 diabetes worldwide.

MariTide is a GLP-1 receptor agonist, a type of drug whose behavior is well-known to reduce weight and control Type 2 diabetes. It differentiates from current competitors like Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro and Zepbound, because it has a distinct molecular structure. MariTide contains a monoclonal antibody that means the drug can remain in the body longer. This capability makes the drug possible to give as a once-monthly injection, a major improvement over its weekly-injected counterparts.

Amgen's Phase 2 clinical trial consisted of almost 600 adults, divided into two groups: one with obesity alone and the other with obesity and Type 2 diabetes. Volunteers were assigned to take one of three dose levels of MariTide or a dummy shot. They took monthly injections for 52 weeks, and some in the obesity group started with a low dose that was increased incrementally.

The findings from the Phase 2 clinical trial of MariTide were nothing short of remarkable. Participants who had obesity but did not have diabetes experienced an average weight loss of up to 20% of their body weight after 52 weeks of treatment. Meanwhile, those who were managing both obesity and Type 2 diabetes saw an average weight loss of up to 17%. In sharp contrast, patients in the placebo groups showed only slight decreases in body weight, 2.6% for the group with obesity alone and only 1.4% for the group with obesity and diabetes. These findings highlight the great potential of MariTide as a very effective, once-a-month weight loss treatment.

These findings place MariTide on par with Wegovy and Zepbound in weight loss effects. Although Wegovy studies recorded a 15% decrease after 68 weeks and Zepbound delivered a 22.5% decrease after 72 weeks, MariTide's monthly regimen and similar effectiveness make it a strong contender.

<h2>Health Benefits of Using MariTide</h2>

MariTide is not only gaining recognition for its effectiveness at weight loss—it's also emerging as a full-range cardiometabolic therapy. Based on trial results, patients on MariTide experienced a dramatic decrease in A1c values, a key measure of long-term blood glucose control. For patients with diabetes, the medication reduced A1c by as much as 2.2 percentage points, outpacing expected decreases of 1.5 to 2.0 points with established GLP-1 therapies such as Ozempic and Mounjaro. But the advantages didn't end there. The research also observed significant reductions in blood pressure, cholesterol, and markers of inflammation, pointing to the potential of MariTide beyond the scale. These results indicate that the drug may provide an all-around solution to obesity as well as other chronic diseases such as cardiovascular disease and type 2 diabetes, making it an attractive option in the changing scenario of metabolic health treatments.

Similar to other GLP-1 receptor agonists, MariTide has a similar action to glucagon-like peptide-1, a hormone that controls blood glucose and hunger. It increases the release of insulin, decreases the release of glucagon, and retards gastric emptying. MariTide differs from other drugs in that it contains a monoclonal antibody that keeps the drug in the body longer. Monthly dosing is made possible by this advance, and treatment compliance may be enhanced by less frequent injections.

<h2>Side Effects of 'MariTide' That People Need to Know</h2>

Similar to other GLP-1 drugs, side effects in the gastrointestinal tract were most frequently reported during the trial. These consisted of:

<ul><li>Nausea</li><li>Vomiting</li><li>Diarrhea</li><li>Abdominal discomfort</li></ul>

The side effect profile was comparable to other drugs in the same class according to the research team and largely tolerable overall. Large-scale Phase 3 trials will be important to best evaluate long-term safety and infrequent adverse events, though.

<h2><span rel="noindex">MariTide vs Wegovy</span>, Mounjaro, and Others</h2>

If approved, MariTide would represent Amgen's foray into a weight loss market led by Novo Nordisk and Eli Lilly. Wegovy and Mounjaro have experienced explosive growth as a result of their robust efficacy results. Yet, MariTide's monthly dosing regimen and dual utility in diabetes care and weight loss may resonate with a vast patient population.

The comparisons between MariTide and existing GLP-1 drugs have not yet been conducted. Still, the early data suggests that Amgen’s candidate could stand toe-to-toe with the industry giants.

Amgen said it plans a Phase 3 clinical trial to further study MariTide for 72 weeks. If all goes well, the results of this research may lead to FDA approval and future distribution worldwide. Most analysts expect it will be at least a couple of years before MariTide is widely available, though.

With rates of obesity on the rise globally and related health issues costing billions each year, effective, affordable, and sustainable weight-loss solutions have never been more vital. MariTide's encouraging results provide a timely new alternative to an expanding stockpile of obesity-fighting weapons.

weight loss injection

maritide weight loss drug

monthly obesity injection

amgen weight loss trial

glp 1 weight loss drugs

maritide vs wegovy

new weight loss medication

fda obesity treatment

A new clinical trial has uncovered the breakthrough promise of a new weight loss medication, MariTide, that can be taken only once monthly. Amgen developed the investigational drug, and it has demonstrated remarkable weight loss outcomes up to 20% in individuals with obesity. The Phase 2 trial results, which were released in The New England Journal of Medicine and presented at the American Diabetes Association's annual meeting 2025, may be a turning point in the treatment of obesity and Type 2 diabetes worldwide.MariTide is a GLP-1 receptor agonist, a type of drug whose behavior is well-known to reduce weight and control Type 2 diabetes. It differentiates from current competitors like Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro and Zepbound, because it has a distinct molecular structure. MariTide contains a monoclonal antibody that means the drug can remain in the body longer. This capability makes the drug possible to give as a once-monthly injection, a major improvement over its weekly-injected counterparts.Amgen's Phase 2 clinical trial consisted of almost 600 adults, divided into two groups: one with obesity alone and the other with obesity and Type 2 diabetes. Volunteers were assigned to take one of three dose levels of MariTide or a dummy shot. They took monthly injections for 52 weeks, and some in the obesity group started with a low dose that was increased incrementally.The findings from the Phase 2 clinical trial of MariTide were nothing short of remarkable. Participants who had obesity but did not have diabetes experienced an average weight loss of up to 20% of their body weight after 52 weeks of treatment. Meanwhile, those who were managing both obesity and Type 2 diabetes saw an average weight loss of up to 17%. In sharp contrast, patients in the placebo groups showed only slight decreases in body weight, 2.6% for the group with obesity alone and only 1.4% for the group with obesity and diabetes. These findings highlight the great potential of MariTide as a very effective, once-a-month weight loss treatment.These findings place MariTide on par with Wegovy and Zepbound in weight loss effects. Although Wegovy studies recorded a 15% decrease after 68 weeks and Zepbound delivered a 22.5% decrease after 72 weeks, MariTide's monthly regimen and similar effectiveness make it a strong contender.Health Benefits of Using MariTideMariTide is not only gaining recognition for its effectiveness at weight loss—it's also emerging as a full-range cardiometabolic therapy. Based on trial results, patients on MariTide experienced a dramatic decrease in A1c values, a key measure of long-term blood glucose control. For patients with diabetes, the medication reduced A1c by as much as 2.2 percentage points, outpacing expected decreases of 1.5 to 2.0 points with established GLP-1 therapies such as Ozempic and Mounjaro. But the advantages didn't end there. The research also observed significant reductions in blood pressure, cholesterol, and markers of inflammation, pointing to the potential of MariTide beyond the scale. These results indicate that the drug may provide an all-around solution to obesity as well as other chronic diseases such as cardiovascular disease and type 2 diabetes, making it an attractive option in the changing scenario of metabolic health treatments.How MariTide Works?Similar to other GLP-1 receptor agonists, MariTide has a similar action to glucagon-like peptide-1, a hormone that controls blood glucose and hunger. It increases the release of insulin, decreases the release of glucagon, and retards gastric emptying. MariTide differs from other drugs in that it contains a monoclonal antibody that keeps the drug in the body longer. Monthly dosing is made possible by this advance, and treatment compliance may be enhanced by less frequent injections.Side Effects of 'MariTide' That People Need to KnowSimilar to other GLP-1 drugs, side effects in the gastrointestinal tract were most frequently reported during the trial. These consisted of:NauseaVomitingDiarrheaAbdominal discomfortThe side effect profile was comparable to other drugs in the same class according to the research team and largely tolerable overall. Large-scale Phase 3 trials will be important to best evaluate long-term safety and infrequent adverse events, though.MariTide vs Wegovy, Mounjaro, and OthersIf approved, MariTide would represent Amgen's foray into a weight loss market led by Novo Nordisk and Eli Lilly. Wegovy and Mounjaro have experienced explosive growth as a result of their robust efficacy results. Yet, MariTide's monthly dosing regimen and dual utility in diabetes care and weight loss may resonate with a vast patient population.The comparisons between MariTide and existing GLP-1 drugs have not yet been conducted. Still, the early data suggests that Amgen’s candidate could stand toe-to-toe with the industry giants.What’s Next for MariTide?Amgen said it plans a Phase 3 clinical trial to further study MariTide for 72 weeks. If all goes well, the results of this research may lead to FDA approval and future distribution worldwide. Most analysts expect it will be at least a couple of years before MariTide is widely available, though.With rates of obesity on the rise globally and related health issues costing billions each year, effective, affordable, and sustainable weight-loss solutions have never been more vital. MariTide's encouraging results provide a timely new alternative to an expanding stockpile of obesity-fighting weapons.

not wegovy or mounjaro or ozempic: this new monthly weight loss jab helped people drop 20% body fat

Global pharma giant Novo Nordisk launched its blockbuster weight loss drug <span>Wegovy</span> in India, a pivotal moment in the battle against increasing obesity levels in the nation. This follows closely on the heels of Eli Lilly's Mounjaro launch in India.

Wegovy, the semaglutide-based GLP-1 receptor agonist, will be available by the end of the month across major pharmacy chains in India. The once-weekly injectable prescription drug has already changed the landscape of obesity management in the United States and Europe.

"One out of every three patients attain 20% weight loss using the increased dose of Wegovy," stated Vikrant Shrotriya, Managing Director, Novo Nordisk India. The firm has completed late-stage trials involving 3,500 people in India, indicating encouraging results in sustained weight loss.

Wegovy will come in several dosages, ranging from Rs 4,336 for 0.25 mg to Rs 26,015 for the highest 2.4 mg dose. Its price is comparable to its rival Mounjaro, which was also launched in India last month in March.

Wegovy is timely given the increasing weight problem in India. A recent National Family Health Survey reveals that 24% of Indian women and 23% of Indian men aged between 15 and 49 years are overweight or obese—a notable increase from past years. India, with a population of over 1.4 billion and fast-emerging lifestyle diseases, is a huge market for weight-loss medications.

The medication has already proven to be successful across the world. Clinical trials have indicated that Wegovy consumers would lose around 15% of their body weight on average, especially when combined with a balanced diet and regular exercise. For comparison, Mounjaro (tirzepatide), being a dual GIP and GLP-1 agonist, experienced close to 23% of weight loss under the same circumstances.

Novo Nordisk's launch in India is at a time of corporate leadership transition, following the recent resignation of CEO Lars Fruergaard Jorgensen. The move is said by analysts to be intended to protect market share in a competitive environment rising from Lilly competition as well as Indian generic drugmakers who are gearing up to move into the field of obesity drugs when semaglutide's patent is about to end in 2026.

Although Wegovy brings new hope to millions of people with obesity, there are warnings with the medication. The drug has a boxed FDA warning about the potential for thyroid cancer, as suggested by studies on animals. Because of this, the drug is not approved for use in someone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).

As India joins the global fight against obesity with cutting-edge therapies, India is all set to benefit from Novo Nordisk's Wegovy, which is ready to provide a new, science-driven solution for long-term weight management. The competition has already turned hot, and for Indian consumers, it could mean more options, improved results, and a new age of obesity treatment.

wegovy

wegovy india launch

obesity drug wegovy

semaglutide injection

weight loss medication india

novo nordisk wegovy

wegovy vs mounjaro

glp-1 weight loss drugs

Global pharma giant Novo Nordisk launched its blockbuster weight loss drug Wegovy in India, a pivotal moment in the battle against increasing obesity levels in the nation. This follows closely on the heels of Eli Lilly's Mounjaro launch in India.Wegovy, the semaglutide-based GLP-1 receptor agonist, will be available by the end of the month across major pharmacy chains in India. The once-weekly injectable prescription drug has already changed the landscape of obesity management in the United States and Europe."One out of every three patients attain 20% weight loss using the increased dose of Wegovy," stated Vikrant Shrotriya, Managing Director, Novo Nordisk India. The firm has completed late-stage trials involving 3,500 people in India, indicating encouraging results in sustained weight loss.Wegovy will come in several dosages, ranging from Rs 4,336 for 0.25 mg to Rs 26,015 for the highest 2.4 mg dose. Its price is comparable to its rival Mounjaro, which was also launched in India last month in March.Wegovy is timely given the increasing weight problem in India. A recent National Family Health Survey reveals that 24% of Indian women and 23% of Indian men aged between 15 and 49 years are overweight or obese—a notable increase from past years. India, with a population of over 1.4 billion and fast-emerging lifestyle diseases, is a huge market for weight-loss medications.The medication has already proven to be successful across the world. Clinical trials have indicated that Wegovy consumers would lose around 15% of their body weight on average, especially when combined with a balanced diet and regular exercise. For comparison, Mounjaro (tirzepatide), being a dual GIP and GLP-1 agonist, experienced close to 23% of weight loss under the same circumstances.Novo Nordisk's launch in India is at a time of corporate leadership transition, following the recent resignation of CEO Lars Fruergaard Jorgensen. The move is said by analysts to be intended to protect market share in a competitive environment rising from Lilly competition as well as Indian generic drugmakers who are gearing up to move into the field of obesity drugs when semaglutide's patent is about to end in 2026.Although Wegovy brings new hope to millions of people with obesity, there are warnings with the medication. The drug has a boxed FDA warning about the potential for thyroid cancer, as suggested by studies on animals. Because of this, the drug is not approved for use in someone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).As India joins the global fight against obesity with cutting-edge therapies, India is all set to benefit from Novo Nordisk's Wegovy, which is ready to provide a new, science-driven solution for long-term weight management. The competition has already turned hot, and for Indian consumers, it could mean more options, improved results, and a new age of obesity treatment.

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Flourishing Doesn't Mean Happiness, Youth Is Struggling, Finds Study

Quick Stories

Measles Outbreak: North Carolina Confirms Its First Case Of 2025

Not Wegovy or Mounjaro Or Ozempic: This New Monthly Weight Loss Jab Helped People Drop 20% Body Fat

Novo Nordisk Launches Bestseller Weight Loss Drug Wegovy In India

Health Conditions A-Z

What Is The Viral Cortisol Cocktail? Does It Really Work?

New Texas Law Could Change Labeling Of Food Additives Across US

Measles Outbreak: North Carolina Confirms Its First Case Of 2025